Literature DB >> 7614997

Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.

S Adams1, R E Humphreys.   

Abstract

Two soluble invariant chain (Ii) peptides with overlapping sequences had contrasting effects on the presentation of antigenic peptides by murine Ad, Ak, Ed, and Ek major histocompatibility complex (MHC) class II molecules. Naturally produced class II-associated invariant chain peptides human (h)Ii81-104/murine (m)Ii80-103 inhibited antigen presentation on these MHC class II alleles in a manner consistent with competitive inhibition. The Ii-4 peptides hIi77-92/mIi76-91 enhanced presentation of antigenic peptides on I-E class II alleles by promoting the exchange of peptides at the cell surface. Treatment of antigen-presenting cells (APC) with Ii-4 before the addition of antigenic peptide greatly enhanced subsequent T cell responses, while treatment of APC with Ii-4 after antigenic peptide binding decreased subsequent T cell responses. The hIi81-104 and mIi80-103 peptides inhibited T cell responses in both types of assays. The binding of biotinylated antigenic peptide to MHC class II-transfected L cells, as measured by flow cytometry, was inhibited by mIi80-103 and enhanced by mIi-4. Segments of Ii fragments remaining associated with MHC class II, or released Ii peptides, appear to regulate the formation of stable antigenic peptide/MHC class II complexes either positively or negatively through interactions at or near the antigenic peptide binding site. These findings open a pathway for the design of novel therapeutics based on the structure and function of natural and rationally designed fragments of Ii.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7614997     DOI: 10.1002/eji.1830250632

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Design of a ProDer f 1 vaccine delivered by the MHC class II pathway of antigen presentation and analysis of the effectiveness for specific immunotherapy.

Authors:  Zhiming Liu; Yuxin Jiang; Chaopin Li
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

2.  MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells.

Authors:  Courtney L Erskine; Christopher J Krco; Karen E Hedin; Nancy D Borson; Kimberly R Kalli; Marshall D Behrens; Sabrina M Heman-Ackah; Eric von Hofe; Peter J Wettstein; Mansour Mohamadzadeh; Keith L Knutson
Journal:  J Immunol       Date:  2011-05-25       Impact factor: 5.422

3.  Resolving multiple protein-peptide binding events: implication for HLA-DQ2 mediated antigen presentation in celiac disease.

Authors:  Jianhao Wang; Xi Jin; Jiahui Liu; Chaitan Khosla; Jiang Xia
Journal:  Chem Asian J       Date:  2012-03-12

4.  Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Authors:  E A Mittendorf; A Ardavanis; J Symanowski; J L Murray; N M Shumway; J K Litton; D F Hale; S A Perez; E A Anastasopoulou; N F Pistamaltzian; S Ponniah; C N Baxevanis; E von Hofe; M Papamichail; G E Peoples
Journal:  Ann Oncol       Date:  2016-03-30       Impact factor: 32.976

5.  Boosting immune response with the invariant chain segments via association with non-peptide binding region of major histocompatibility complex class II molecules.

Authors:  Fangfang Chen; Fantao Meng; Ling Pan; Fazhi Xu; Xuelan Liu; Weiyi Yu
Journal:  BMC Immunol       Date:  2012-09-27       Impact factor: 3.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.